Assessment of Hemodynamic Parameters by Type of Anemia in Children with Chronic Kidney Disease
Keywords:
anemia, chronic kidney disease, anemia of chronic disease, serum iron, serum ferritin, transferrin, erythropoietin, hepcidin.
Abstract
The article presents the diagnostic significance and comparison of hemodynamic and cytokine indicators in different types of anemia in children with chronic kidney disease. Values of iron metabolism indicators (serum iron and ferritin, transferrin), hemoregulatory hormones (erythropoietin and hepcidin), and blood inflammation markers (IL-6 and TNF-α) were identified. Functional anemia in children is more severe compared to absolute anemia. Thus, laboratory diagnostics should be conducted for all patients with chronic kidney disease, starting in the early stages of the disease.
References
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012; 2: 279–335.
Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy ZA. Emerging biomarkers for the risk stratification in cardiovascular disease and chronic kidney disease: a review. Am J Kidney Dis. 2008; 51: 212–227.
Eknoyan G, Levin NW. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1–S266.
National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007; 49: S12–S154.
Ketteler M, Wanner C, Metzger T, Rieger J, Floege J. Towards a new definition of chronic kidney disease. Eur J Clin Invest. 2013; 43: 34–41.
Ministry of Health of the Republic of Uzbekistan. Annual report on the health status of the population of Uzbekistan for 2013. Tashkent, 2014.
Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352: 1011–1023.
Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program. 2006: 29–35.
Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant. 2002; 17: 48–52.
Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougall IC, Macleod A, Wiecek A, Cameron S. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19: ii1–ii47.
Demirkol M, Özkaya O, Turkmen K, Sezgin N, Tonbul HZ, Erdemir F, Sipahioglu MH, Tokgoz B. Prevalence of chronic kidney disease in children and adolescents in a Turkish population. Kidney Blood Press Res. 2015; 40: 490–497.
Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: Sources, consequences, and therapy. Semin Dial. 2002; 15: 329–337.
Mehrotra R, Kermah D, Salusky IB, Wolf MS, Thadhani R, Chiu YW, Martins D, Adler S, Norris K. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009; 76: 977–983.
Chavers BM, Roberts TL, Herzog CA, Collins AJ. Association of dialysis modality and cardiovascular mortality in children with end-stage renal disease. Kidney Int. 2005; 68: 167–172.
Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015; 39: 84–92.
Akchurin OM, Melamed ML. Has the time come to screen children for chronic kidney disease? Pediatr Nephrol. 2016; 31: 1117–1129.
Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004; 15: S77–S80.
Silverberg D, Wexler D, Blum M, Wollman Y, Iaina A. The association between congestive heart failure and anemia in adults: A prospective evaluation. Am J Med. 2001; 111: 241–247.
Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009; 122: 78–86.
Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities’ study. J Am Soc Nephrol. 2005; 16: 529–538.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296–1305.
Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol. 1998; 11: 239–245.
Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011; 80: 17–28.
Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006; 144: 21–28.
Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Zoccali C. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014; 383: 1831–1843
Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy ZA. Emerging biomarkers for the risk stratification in cardiovascular disease and chronic kidney disease: a review. Am J Kidney Dis. 2008; 51: 212–227.
Eknoyan G, Levin NW. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1–S266.
National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007; 49: S12–S154.
Ketteler M, Wanner C, Metzger T, Rieger J, Floege J. Towards a new definition of chronic kidney disease. Eur J Clin Invest. 2013; 43: 34–41.
Ministry of Health of the Republic of Uzbekistan. Annual report on the health status of the population of Uzbekistan for 2013. Tashkent, 2014.
Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352: 1011–1023.
Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program. 2006: 29–35.
Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant. 2002; 17: 48–52.
Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougall IC, Macleod A, Wiecek A, Cameron S. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19: ii1–ii47.
Demirkol M, Özkaya O, Turkmen K, Sezgin N, Tonbul HZ, Erdemir F, Sipahioglu MH, Tokgoz B. Prevalence of chronic kidney disease in children and adolescents in a Turkish population. Kidney Blood Press Res. 2015; 40: 490–497.
Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: Sources, consequences, and therapy. Semin Dial. 2002; 15: 329–337.
Mehrotra R, Kermah D, Salusky IB, Wolf MS, Thadhani R, Chiu YW, Martins D, Adler S, Norris K. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009; 76: 977–983.
Chavers BM, Roberts TL, Herzog CA, Collins AJ. Association of dialysis modality and cardiovascular mortality in children with end-stage renal disease. Kidney Int. 2005; 68: 167–172.
Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015; 39: 84–92.
Akchurin OM, Melamed ML. Has the time come to screen children for chronic kidney disease? Pediatr Nephrol. 2016; 31: 1117–1129.
Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004; 15: S77–S80.
Silverberg D, Wexler D, Blum M, Wollman Y, Iaina A. The association between congestive heart failure and anemia in adults: A prospective evaluation. Am J Med. 2001; 111: 241–247.
Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009; 122: 78–86.
Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities’ study. J Am Soc Nephrol. 2005; 16: 529–538.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296–1305.
Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol. 1998; 11: 239–245.
Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011; 80: 17–28.
Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006; 144: 21–28.
Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Zoccali C. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014; 383: 1831–1843
Published
2024-07-29
How to Cite
Ashurova N. Sh., & Mukhamadiev N.Q. (2024). Assessment of Hemodynamic Parameters by Type of Anemia in Children with Chronic Kidney Disease. Central Asian Journal of Medical and Natural Science, 5(4), 230-238. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/2544
Section
Articles
